Scott Ewing, DO
Interventional Cardiology · Fort Worth, TXNPI 1760461800
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,165 of the $14,891 with a category attached, or 88.4%. 41 manufacturers reported payments, led by Medtronic at 30.2% of the total. Reporting peaked in 2019 at $4,029 and has fallen 59.4% since, to $1,636 in 2025.
Across 352 payments — averaging $42.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Boston Scientific$2K
- Abiomed$1K
- Novartis$1K
- Pfizer$950
- Shockwave Medical, Inc$770
- plus $4K from 35 others
Across 96 payments — averaging $2065.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$134K
- Boston Scientific$65K
What the payments were for
- Travel & lodging$1,49010%
- Food & beverage$13,16588%
- Education$2372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,755
- Impella$816
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$691
- ONYX FRONTIER$556
- AVVIGO Guidance System$422
- OPTICROSS$268
- Orsiro Mission$251
- Indigo System$247
- Resolute$241
- OptiCross 6$237
- GENERAL - THERAPIES$228
- Barostim Neo System$185
- TRICLIP$167
- Fortify Assura$158
- Indigo$144
- Abre$139
- Visia AF$139
- FFRct$132
- Vascepa$125
- FARXIGA$125
How this compares
$14,891 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 549 | $504,168 |
| EntrestoSacubitril/Valsartan | 127 | $128,547 |
| XareltoRivaroxaban | 57 | $69,354 |
| JardianceEmpagliflozin | 17 | $28,044 |
| MultaqDronedarone Hcl | 16 | $18,289 |
| VascepaIcosapent Ethyl | 25 | $15,485 |
| Repatha SureclickEvolocumab | 16 | $13,606 |
| FarxigaDapagliflozin Propanediol | 12 | $7,894 |
| Repatha SyringeEvolocumab | 12 | $6,457 |
| Metoprolol Succinate | 263 | $3,937 |
| Flecainide Acetate | 106 | $3,702 |
| Rosuvastatin Calcium | 278 | $3,608 |
| Icosapent Ethyl | 16 | $3,115 |
| Midodrine Hcl | 32 | $2,354 |
| Valsartan | 65 | $2,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $950 | $504,168549 claims |
| NovartisEntresto | $1,020 | $128,547127 claims |
| Johnson & JohnsonXarelto | $330 | $69,35457 claims |
| Boehringer IngelheimJardiance | $150 | $28,04417 claims |
| Sanofi-aventis U.S. LLCMultaq | $37 | $18,28916 claims |
| AstraZenecaFarxiga | $398 | $7,89412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Fort Worth
- Elizabeth HolperFort Worth$206K
- Amir MalikFort Worth$136K
- Sukesh BurjonroppaFort Worth$130K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.